NCT01332604View on ClinicalTrials.gov

GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

41

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions

Solid Cancers

Interventions

DRUG

GDC-0980

Oral escalating dose

DRUG

bevacizumab

Intravenous repeating dose

DRUG

capecitabine

Oral repeating dose

DRUG

mFOLFOX6

Intravenous repeating dose

Trial Locations (4)

55905

Rochester

80045

Aurora

90095

Los Angeles

08035

Barcelona

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY